Latest News - Regeneron Pharmaceuticals
Top Corporates Hub
Regeneron Pharmaceuticals
Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron?
08.10.2026 06:18
In September 2026, Biohaven Ltd. announced a clinical supply agreement with Regeneron Pharmaceuticals to test BHV-1530 in combination with cemiplimab (Libtayo) in patients with solid tumors, following earlier monotherapy and preclinical data suggesting potential synergy with Anti-PD-1 therapy. This new BHV-1530 collaboration builds on an existing supply agreement for Biohaven’s next-generation TROP2-directed ADC BHV-1510, deepening Regeneron’s involvement across Biohaven’s oncology...
Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals
03.10.2026 00:13
Biotech companies this week spent on experimental therapies, including autoimmune drugs, next-generation obesity pills and cancer combinations.
Which S&P500 stocks are moving on Thursday?
01.10.2026 16:35
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript
01.10.2026 15:50
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies October 1, 2026 8:00 AM...
Sanofi, Regeneron broaden alliance to find their next Dupixent
01.10.2026 15:38
The deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after the same targets as their blockbuster anti-inflammation agent.
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
01.10.2026 15:35
LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemotherapy Results presented in a late-breaking plenary session at IGCS demonstrated a 73% objective response rate and 11-month median progression-free survival in 11 patients with recurrent and heavily pre-treated LGSOC treated with the highest dose of ubamatamab in the trial Regeneron has been enrolling a dedicated LGSOC cohort at this dose and will ad
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
01.10.2026 15:30
In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had greater loss of lean mass with semaglutide, and more preservation with trevogrumab Findings were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting and is in press with The Lancet TARRYTOWN, N.Y., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharm
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion
01.10.2026 15:02
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases, adding four Regeneron-originated antibody programs and establishing a new equal-sharing economic framew
Sanofi and Regeneron expand immunology partnership to the tune of $8bn
01.10.2026 11:40
The agreement will see Sanofi and Regeneron co-develop and co-commercialise four long-lasting antibodies.
Regeneron, Sanofi Expand Immunology Alliance With $1B Upfront Payment: Here Are The Key Highlights
01.10.2026 11:36
Sanofi and Regeneron are broadening their immunology pipeline while keeping their existing Dupixent economics intact.
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies - Slideshow
01.10.2026 10:51
2026-10-01. The following slide deck was published by Regeneron Pharmaceuticals, Inc.
Regeneron Exec Says Co. Eligible To Receive $1B In Potential Milestone Payment With Start Of First Late-Stage Trial As Part Of Deal
01.10.2026 08:51
https://edge.media-server.com/mmc/p/dfer26i6/
Argus Research Upgrades Regeneron Pharmaceuticals to Buy, Announces $850 Price Target
01.10.2026 08:40
Argus Research analyst Jasper Hellweg upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Hold to Buy and announces $850 price target.
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion
01.10.2026 06:27
The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.
Sanofi, Regeneron expand partnership in deal worth up to $8 billion
01.10.2026 06:00
Investing.com -- Sanofi SA (EPA:SASY) will pay Regeneron $1 billion upfront and up to $7 billion in additional payments to expand their partnership on four new long-acting medicines for inflammatory diseases, as the French drugmaker looks to build its pipeline beyond its blockbuster Dupixent treatment.
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
01.10.2026 05:00
Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the Alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting pre-clinical antibodies from RegeneronRegeneron to receive $1 billion upfront, with potential for up to an additional $7 billion in future milestone payments; companies to equally share dev
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
01.10.2026 05:00
REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical antibodies from Regeneron Regeneron to receive $1 billion upfront with potential for up to an additional $7 billion in future milestone payments; companies to equally share development and commercialization costs, as well as any future profits Regeneron and Sanofi to host a conference
Sanofi Expands Regeneron Alliance With Four Long-Acting Antibodies, Paying $1B Upfront With Up To $7B In Milestones; Costs And Profits Shared Equally
01.10.2026 01:48
REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
30.09.2026 12:05
Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing the move.
MRNA Stock Falls Premarket After Citi Downgrade: Analyst Says Valuation Looks Stretched Despite Cancer Vaccine Momentum
30.09.2026 12:03
Citi downgraded Moderna to 'Sell' on valuation concerns after a massive 2026 rally, while investors await detailed Phase 3 melanoma data at ESMO next month.